注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Leap Therapeutics Inc是一家生物技术公司。该公司专注于开发靶向和免疫肿瘤疗法。其先进的临床候选药物DKN-01是一种针对Dickkopf-1(DKK1)蛋白的人源化单克隆抗体。DKN-01正在为食管胃癌、妇科癌和结直肠癌患者开发。DKK1调节Wnt/β-连环蛋白和PI3激酶/AKT信号通路,促进肿瘤增殖、转移、血管生成,并通过增强髓源性抑制细胞的活性和下调肿瘤细胞上的NK细胞配体来介导免疫抑制性肿瘤微环境。该公司的产品线包括FL-301,一种针对Claudin18.2的人源化单克隆抗体,正在为胃癌和胰腺癌患者开发。Claudin18.2调节屏障特性并促进细胞间粘附。它还有针对Claudin18.2/CD137和GDF15的临床前抗体项目。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Douglas E. Onsi | 52 | 2011 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director |
Christopher K. Mirabelli | 67 | 2011 | Chairman |
James H. Cavanaugh | 84 | 2016 | Independent Director |
Thomas John Dietz | 57 | 2016 | Lead Independent Director |
Joseph Loscalzo | 70 | 2016 | Independent Director |
William W. Li | 58 | 2017 | Independent Director |
Carl F. Nathan | - | - | Member of Scientific Advisory Board |
David Tuveson | - | - | Member of Scientific Advisory Board |
Nissim Mashiach | 60 | 2017 | Independent Director |
Andrew B Nixon | - | 2021 | Member of Scientific Advisory Board |
Richard B. Gaynor | 73 | 2021 | Member of Scientific Advisory Board |
Eileen M. O’Reilly | - | 2022 | Member of Scientific Advisory Board |
Richard L. Schilsky | 73 | 2022 | Independent Director |
Patricia Martin | 63 | 2023 | Independent Director |
Scott Joseph Antonia | - | 2023 | Member of Scientific Advisory Board |
Christian M. Richard | 54 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核